Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_assertion type Assertion NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_head.
- NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_assertion description "[In December 2014, a poly(ADP-ribose) polymerase (PARP) inhibitor was granted expedited approved by the United States Food and Drug Administration for use in advanced ovarian cancer patients with germline BRCA1/2 mutations who have received three or more prior lines of chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_provenance.
- NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_assertion evidence source_evidence_literature NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_provenance.
- NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_assertion SIO_000772 25725131 NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_provenance.
- NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_assertion wasDerivedFrom befree-2016 NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_provenance.
- NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_assertion wasGeneratedBy ECO_0000203 NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_provenance.